Global Innovative Platforms GIPL
OTC GIPL
$0.50 +0.00 (+0.00%)
At close: Sep 28, 2026 · 4:00 PM EDT

Global Innovative Platforms (GIPL) Capital Expenditures (2026)

Updated

Global Innovative Platforms' Capital Expenditures was $55,116 in fiscal Q3 2026 (quarter ended Jun 30, 2026).

Analysis

Global Innovative Platforms (GIPL) Capital Expenditures (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 1.32 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 322.00 Mn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 893.00 Mn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -321.00 Mn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -763.00 Mn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 513.00 Mn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 140.00 Mn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 533.00 Mn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 112.20 Mn
10 Global Innovative Platforms 24.88 Mn 24.27 Mn - 55,116.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 55,116.00
API Access

Global Innovative Platforms Capital Expenditures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-expenditures&ticker=GIPL&period=max&api_key=YOUR_API_KEY